9781489938398 - Novel Anticancer Drug Protocols: 85 (Methods in Molecular Medicine) (12 resultados)

Condición: New. In.

Condición: New. Editor(s): Buolamwini, John K.; Adjei, Alex A. Series: Methods in Molecular Medicine. Num Pages: 355 pages, biography. BIC Classification: MQP. Category: (P) Professional & Vocational. Dimension: 229 x 152 x 20. Weight in Grams: 550. . 2013. Softcover reprint of the original 1st ed. 2003. Paperback. . . . .

Taschenbuch. Condición: Neu. Novel Anticancer Drug Protocols | Alex A. Adjei (u. a.) | Taschenbuch | xvi | Englisch | 2013 | Humana Press | EAN 9781489938398 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Condición: New. pp. 378.

Paperback. Condición: Brand New. reprint edition. 371 pages. 9.01x5.98x0.89 inches. In Stock.

Condición: New. Editor(s): Buolamwini, John K.; Adjei, Alex A. Series: Methods in Molecular Medicine. Num Pages: 355 pages, biography. BIC Classification: MQP. Category: (P) Professional & Vocational. Dimension: 229 x 152 x 20. Weight in Grams: 550. . 2013. Softcover reprint of the original 1st ed. 2003. Paperback. . . . . Books ship from the US and Ireland.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin® (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia. 376 pp. Englisch.

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Includes supplementary material: sn.pub/extrasWe are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cyt.

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin® (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 376 pp. Englisch.

Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin® (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.

Condición: New. Print on Demand pp. 378.

Condición: New. PRINT ON DEMAND pp. 378.